TransMedics Group, Inc. (TMDX) Enterprise Value (EV): $2.70B
The enterprise value (EV) for TransMedics Group, Inc. (TMDX) is $2.70B as of Saturday, June 20, 2026.
TMDX Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$2.70B
TMDX Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.72B | $2.70B |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | $4.42B |
| 23andMe Holding Co. (ME)vs › | $15.31M | $49.27M |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | $9.26B |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | $8.20B |
| Tempus AI, Inc. (TEM)vs › | $8.87B | $11.01B |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | $12.95B |
| Baxter International Inc. (BAX)vs › | $10.27B | $17.84B |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | $40.43B |
| Revvity, Inc. (RVTY)vs › | $11.16B | $13.59B |
Enterprise Value Calculation
Market Cap
$2.72B
Total Debt
$469.69M
Cash
$488.37M
Enterprise Value
$2.70B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
TransMedics Group, Inc. Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for TransMedics Group, Inc. (TMDX)?
- The enterprise value (EV) for TMDX stock is $2.70B.
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein